Clinical Focus

  • Medical Oncology

Academic Appointments

Professional Education

  • Board Certification: American Board of Internal Medicine, Medical Oncology (2024)
  • Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2013) MA
  • Residency: Brigham and Women's Hospital Internal Medicine Residency (2010) MA
  • Medical Education: Harvard Medical School (2007) MA

Contact

  • Academic
    lgoyal@stanford.edu
    University - Faculty Department: Medicine - Med/Oncology Position: Associate Professor
  • Clinical (Primary)  Stanford Cancer Center 875 Blake Wilbur Dr Clinic A MC 6560 Stanford, CA 94305 (650) 498-6000 (fax)

Additional Clinical Info

Clinical Trials

  • Phase II AZD0901 +/- Combo w/ Anti-Cancer Agents in Advanced Solid Tumours Expressing Claudin 18.2. Recruiting

    The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.

    View full details

  • Phase III Oral Tinengotinib vs Physician's Choice in Relapsed / Refractory Cholangiocarcinoma Recruiting

    This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma

    View full details

  • CGT4859 for the Treatment of FGFR2/3-Altered Solid Tumors Not Recruiting

    This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.

    Stanford is currently not accepting patients for this trial.

    View full details

  • Phase III Rilvegostomig in Combo w/ ChemoTx as Adjuvant Tx After Resection of Biliary Tract Cancer Not Recruiting

    A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.

    Stanford is currently not accepting patients for this trial.

    View full details

  • Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors Not Recruiting

    This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of biomarkers of XL092 administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in subjects with advanced solid tumors. In the Expansion Stage, the safety and efficacy of XL092 as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.

    Stanford is currently not accepting patients for this trial.

    View full details

2025-26 Courses